Edwards Lifesciences Corp: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Jul 29, 2022 and accepted by EDGAR at Jul 29, 2022, 16:55 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $1.37bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $2.72bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-04-01 to 2022-06-30 | $269.4m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2022-01-01 to 2022-06-30 | $568.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2022-04-01 to 2022-06-30 | $1.10bn | us-gaap:GrossProfit |
| Gross profit | 6 months2022-01-01 to 2022-06-30 | $2.15bn | us-gaap:GrossProfit |
| Research and development | 3 months2022-04-01 to 2022-06-30 | $250.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2022-01-01 to 2022-06-30 | $479.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-04-01 to 2022-06-30 | $409.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2022-01-01 to 2022-06-30 | $779.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | $459.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | $898.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-04-01 to 2022-06-30 | $58.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2022-01-01 to 2022-06-30 | $120.8m | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | $0.65 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | $1.24 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | $0.65 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | $1.26 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 626,700,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 628,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | $625.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $115.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2022-01-01 to 2022-06-30 | $760.7m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-06-30 | $1.20bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $3.26bn | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $8.43bn | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $969.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $2.48bn | us-gaap:Liabilities |
| Long-term debt | At period end2022-06-30 | $596.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2022-06-30 | $5.94bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001099800-22-000020. Last ingested by Listed: Nov 15, 2026, 03:19 ET. Listed shows no prices and gives no investment advice.